Register Login
Register to leave comments
  • News bot April 17, 2026, 12:07 p.m.

    📋 TREVI THERAPEUTICS, INC. (TRVI) - Clinical Trial Update

    Filing Date: 2026-04-17

    Accepted: 2026-04-17 08:06:31

    Event Type: Clinical Trial Update

    Event Details:

    TREVI THERAPEUTICS, INC. (TRVI) Announces Clinical Trial Update TREVI THERAPEUTICS, INC. (TRVI) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: shares, cough
    • Diseases/Conditions: idiopathic
    • Collaboration: Morgan Stanley
      • targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995

    🔬 Clinical Development Pipeline (TREVI THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    Nalbuphine ER DRUG Phase PHASE1 Hepatic Impairment ClinicalTrials.gov
    Nintedanib DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Pirfenidone DRUG Phase PHASE1 Healthy Participants ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    NAL ER DRUG Phase PHASE2 Idiopathic Pulmonary Fibrosis ClinicalTrials.gov
    Placebo solution DRUG Phase PHASE1 Nalbuphine ClinicalTrials.gov
    Nalbuphine HCl solution DRUG Phase PHASE1 Nalbuphine ClinicalTrials.gov
    Placebo Tablets DRUG Phase PHASE2 Prurigo Nodularis ClinicalTrials.gov
    Nalbuphine ER Tablets DRUG Phase PHASE2 Prurigo Nodularis ClinicalTrials.gov
    Nalbuphine HCL ER DRUG Phase PHASE1 Uremic Pruritus ClinicalTrials.gov
    nalbuphine HCl ER tablets 180 mg BID DRUG Phase PHASE2 Prurigo Nodularis ClinicalTrials.gov
    nalbuphine HCl ER tablets 90 mg BID DRUG Phase PHASE2 Prurigo Nodularis ClinicalTrials.gov
    Placebo tablets BID DRUG Phase PHASE2 Uremic Pruritus ClinicalTrials.gov
    nalbuphine HCl ER tablets 120mg BID DRUG Phase PHASE2 Uremic Pruritus ClinicalTrials.gov
    nalbuphine HCl ER tablets 60 mg BID DRUG Phase PHASE2 Uremic Pruritus ClinicalTrials.gov

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: TREVI THERAPEUTICS, INC.
    • Ticker Symbol: TRVI

Search

News categories